Jonathan Ledermann

Jonathan Ledermann, MD, FRCP, FMedSci is Emeritus Professor of Medical Oncology at the UCL Cancer Institute and formerly Director of the Cancer Research UK and UCL Cancer Trials Centre, where he oversaw one of the UK's most productive clinical trial portfolios in gynecologic oncology. He is one of the founders of modern PARP inhibitor therapy in ovarian cancer, having led the pivotal Study 19 trial — the randomized phase II study that provided the first definitive proof-of-concept for olaparib maintenance in platinum-sensitive recurrent BRCA-mutant ovarian cancer — and subsequently led SOLO-2, the phase III confirmatory maintenance trial demonstrating a dramatic PFS benefit (19.1 versus 5.5 months, HR 0.30) with olaparib in BRCA-mutant platinum-sensitive recurrent ovarian cancer. He was also a co-lead investigator on SOLO-1, the landmark phase III trial establishing olaparib frontline maintenance in BRCA-mutant newly diagnosed advanced ovarian cancer, which showed a 70% reduction in the risk of disease progression and transformed first-line ovarian cancer management. Professor Ledermann has also contributed to seminal work on ovarian cancer biology including the prognostic role of BRCA mutations, the clinical significance of platinum sensitivity, and the molecular characterization of high-grade serous ovarian cancer. He has served as co-chair of the GCIG and the CRUK Trials Advisory Panel, and is a Fellow of the Academy of Medical Sciences. His career encompasses over 300 publications and has directly shaped regulatory approvals of olaparib across multiple jurisdictions.